Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 27,421,022
  • Shares Outstanding, K 224,560
  • Annual Sales, $ 3,084 M
  • Annual Income, $ 399,000 K
  • 36-Month Beta 1.45
  • Price/Sales 9.11
  • Price/Cash Flow 20.83
  • Price/Book 3.17

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.84 +29.92%
on 05/30/17
130.02 -3.24%
on 06/23/17
+28.11 (+28.77%)
since 05/26/17
3-Month
96.18 +30.81%
on 05/26/17
133.67 -5.88%
on 05/02/17
+7.28 (+6.14%)
since 03/28/17
52-Week
96.18 +30.81%
on 05/26/17
145.41 -13.48%
on 11/04/16
+10.87 (+9.46%)
since 06/28/16

Most Recent Stories

More News
Top Stock Reports for Oracle, Allergan & Abbott

Top Stock Reports for Oracle, Allergan & Abbott

ABT : 48.48 (-0.39%)
VLO : 67.47 (+0.99%)
AGN : 246.71 (+0.25%)
ADBE : 143.81 (+0.89%)
ORCL : 50.87 (+0.24%)
ALXN : 125.81 (+3.03%)
Alexion Receives Positive CHMP Opinion for Soliris(R) (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...

ALXN : 125.81 (+3.03%)
Today's Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Alexion Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / June 21, 2017 / Regeneron's shares were down and then way up in yesterday's trading session. Shares dropped after Novartis released clinical trial data on an experimental drug...

NVS : 85.25 (-0.07%)
REGN : 513.19 (+2.20%)
ALXN : 125.81 (+3.03%)
Watch for Alexion Pharmaceuticals to Potentially Pullback After Gaining 3.16% Yesterday

Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $116.66 to a high of $120.75. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day...

ALXN : 125.81 (+3.03%)
BUYINS.NET: ALXN SqueezeTrigger Price is $119.60. There is $480,836,221 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in real time and just received an alert that ALXN is crossing above its primary SqueezeTrigger Price, the price that...

ALXN : 125.81 (+3.03%)
Company News for June 15, 2017

Companies in the News are: HRB,ALXN,UPS,NAME

UPS : 110.08 (+0.37%)
HRB : 30.74 (-1.91%)
NAME : 10.83 (+0.93%)
ALXN : 125.81 (+3.03%)
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug

Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.

CELG : 134.23 (+2.58%)
XLRN : 31.50 (+6.28%)
ABBV : 72.92 (+0.73%)
GILD : 71.92 (+1.80%)
AMGN : 174.07 (+1.88%)
ALXN : 125.81 (+3.03%)
BIIB : 274.64 (+1.25%)
Today's Research Reports on Stocks to Watch: Epizyme and Alexion Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / June 15, 2017 / Epizyme's shares exploded in Wednesday trading after releasing positive efficacy data results from its phase II clinical trial of Tazemetostat. Alexion Pharmaceuticals...

MS : 44.32 (+0.23%)
EPZM : 15.25 (+6.64%)
ALXN : 125.81 (+3.03%)
Biogen Loses Top Executive Again, CFO Clancy to Join Alexion

Biogen Inc.'s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month.

BAYRY : 138.9900 (+1.02%)
PEP : 116.38 (+0.38%)
ALXN : 125.81 (+3.03%)
BIIB : 274.64 (+1.25%)
Omeros (OMER) Lead Candidate Gets Breakthrough Designation

Omeros Corporation (OMER) announced that the FDA granted breakthrough therapy designation to pipeline candidate OMS721.

VVUS : 1.20 (unch)
MEIP : 2.44 (+4.27%)
OMER : 20.34 (-9.48%)
ALXN : 125.81 (+3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system...

See More

Support & Resistance

2nd Resistance Point 129.62
1st Resistance Point 127.72
Last Price 125.81
1st Support Level 122.71
2nd Support Level 119.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.